Information Provided By:
Fly News Breaks for March 16, 2018
ADAP
Mar 16, 2018 | 08:43 EDT
Leerink analyst Jonathan Chang assumed coverage of Adaptimmune Therapeutics with an Outperform rating and $15 price target. The company's T-cell receptor platform could potentially address solid tumors, which would be transformational for the cell therapy space if successful, Chang tells investors in a research note. HE views Adaptimmune as a leader in the "potentially disruptive" T-cell receptor field.
News For ADAP From the Last 2 Days
There are no results for your query ADAP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.